Ambroxol
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Ambroxol: From Pharyngitis to Nasal Cavity Disease
One-Sentence Summary
Ambroxol is a mucolytic/secretolytic agent, originally used for pharyngitis and related upper respiratory conditions. The TxGNN model predicts it may be effective for nasal cavity disease, but currently there are 0 clinical trials and only 1 publication (an indirect review on acute cough) supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pharyngitis (from the knowledge graph; the Singapore licences contain no approved indication text) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, ambroxol is a mucolytic/secretolytic agent that increases airway mucus clearance. It also has reported local anaesthetic (sodium channel blocking) and anti-inflammatory properties.
Pharyngitis and nasal cavity disease are both upper airway mucosal conditions. Improved mucus clearance and local symptom relief could plausibly benefit the nasal mucosa as well. However, this reasoning rests on general pharmacology rather than on the supplied data, and the only linked publication addresses acute cough, which is indirect evidence for nasal disease.
Other predictions for this drug include acute laryngopharyngitis (99.88%), which is anatomically close to the original indication. Most lower-ranked predictions, such as vulvar, vaginal and cervical disc conditions, have no identifiable mechanistic link and appear to be model artefacts.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26525480 | 2015 | Review | Vestnik otorinolaringologii | Discusses new options for treating acute cough associated with influenza and acute respiratory viral infection (ARVI). Indirect evidence for nasal cavity disease |
Singapore Market Information
Ten single-ingredient licences are currently valid. The licence data contain no approved indication text. Up to five are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13373P | Mucosolvan 24 Hours Capsule 75mg | Capsule, delayed release | Not stated |
| SIN10547P | Mucoclear Syrup 30 mg/5 ml | Syrup | Not stated |
| SIN02696P | Mucosolvan Tablet 30 mg | Tablet | Not stated |
| SIN02983P | Amxol Tablets 30 mg | Tablet | Not stated |
| SIN07180P | Shinoxol Tablets 30 mg | Tablet | Not stated |
Safety Considerations
- Drug Interactions: One pharmacology-based entry was found. Ambroxol acts on glucosylceramidase beta (GBA1). It behaves as an inhibitory chaperone at neutral pH, but increases intracellular enzyme activity within acidic lysosomes. This is a target interaction rather than a clinically graded drug-drug interaction.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no registered clinical trials, and the only publication is an indirect review on acute cough. The mechanism rests on general pharmacology, and the package insert safety data have not been reviewed, so there is not enough evidence to advance.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Detailed mechanism of action data (MOA) from DrugBank
- Targeted literature and trial searches for ambroxol in nasal and upper airway disease
- Confirmation that the existing dosage forms suit the target condition
- Consideration of acute laryngopharyngitis as a closer extension of the original indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.